METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT PATIENTS SUFFERING FROM MYELOPROLIFERATIVE DISORDERS

The present invention relates to methods and pharmaceutical compositions for the treatment of myeloproliferative disorders in patients presenting a dysregulation of the JAK2-STAT signalling pathway. Using MPN mouse model and clonogenic methyl-cellulose cultures of patient progenitors, the inventors...

Full description

Saved in:
Bibliographic Details
Main Authors VILLEVAL, Jean-Luc, CASSINAT, Bruno, DE THE, Hugues, KILADJIAN, Jean-Jacques, LALLEMAND-BREITENBACH, Valérie, PLO, Isabelle
Format Patent
LanguageEnglish
Published 12.12.2019
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to methods and pharmaceutical compositions for the treatment of myeloproliferative disorders in patients presenting a dysregulation of the JAK2-STAT signalling pathway. Using MPN mouse model and clonogenic methyl-cellulose cultures of patient progenitors, the inventors demonstrate that combining ARS with IFN improves most of the benefits provided by IFN alone during MPN treatment. In particular, the present invention relates to a method of treating a myeloproliferative disorder in a patient presenting a dysregulation of the JAK2-STAT signalling pathway comprising administering to the patient a therapeutically effective combination of an interferon polypeptide and an arsenic compound.
Bibliography:Application Number: US201816478662